Brexucabtagene Autoleucel (Tecartus®). HTA ID: 23045

Assessment Status Full HTA submission received from Applicant
HTA ID 23045
Drug Brexucabtagene Autoleucel
Brand Tecartus®
Indication Adults 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
Assessment Process
Rapid review commissioned 24/07/2023
Rapid review completed 10/08/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brexucabtagene autoleucel compared with the current standard-of-care.
Full pharmacoeconomic assessment commissioned by HSE 31/08/2023
Pre-submission consultation with Applicant 09/10/2023
Full submission received from Applicant 18/01/2024